MX2024004012A - Anticuerpos anti-galectina-9 y usos terapéuticos de estos. - Google Patents
Anticuerpos anti-galectina-9 y usos terapéuticos de estos.Info
- Publication number
- MX2024004012A MX2024004012A MX2024004012A MX2024004012A MX2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A
- Authority
- MX
- Mexico
- Prior art keywords
- galectin
- antibodies
- therapeutic uses
- tislelizumab
- igg4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251227P | 2021-10-01 | 2021-10-01 | |
| US202163277384P | 2021-11-09 | 2021-11-09 | |
| PCT/US2022/077408 WO2023056461A1 (en) | 2021-10-01 | 2022-09-30 | Anti-galectin-9 antibodies and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004012A true MX2024004012A (es) | 2024-07-01 |
Family
ID=85783695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004012A MX2024004012A (es) | 2021-10-01 | 2022-09-30 | Anticuerpos anti-galectina-9 y usos terapéuticos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250269019A1 (https=) |
| EP (1) | EP4392068A4 (https=) |
| JP (1) | JP2024536201A (https=) |
| KR (1) | KR20240082393A (https=) |
| AU (1) | AU2022355201A1 (https=) |
| CA (1) | CA3233331A1 (https=) |
| IL (1) | IL311796A (https=) |
| MX (1) | MX2024004012A (https=) |
| WO (1) | WO2023056461A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
-
2022
- 2022-09-30 MX MX2024004012A patent/MX2024004012A/es unknown
- 2022-09-30 CA CA3233331A patent/CA3233331A1/en active Pending
- 2022-09-30 KR KR1020247014491A patent/KR20240082393A/ko active Pending
- 2022-09-30 JP JP2024519470A patent/JP2024536201A/ja active Pending
- 2022-09-30 IL IL311796A patent/IL311796A/en unknown
- 2022-09-30 WO PCT/US2022/077408 patent/WO2023056461A1/en not_active Ceased
- 2022-09-30 EP EP22877637.3A patent/EP4392068A4/en active Pending
- 2022-09-30 AU AU2022355201A patent/AU2022355201A1/en active Pending
- 2022-09-30 US US18/697,500 patent/US20250269019A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3233331A1 (en) | 2023-04-06 |
| JP2024536201A (ja) | 2024-10-04 |
| IL311796A (en) | 2024-05-01 |
| EP4392068A4 (en) | 2026-03-11 |
| AU2022355201A1 (en) | 2024-04-04 |
| WO2023056461A1 (en) | 2023-04-06 |
| EP4392068A1 (en) | 2024-07-03 |
| KR20240082393A (ko) | 2024-06-10 |
| US20250269019A1 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| MX2019012811A (es) | Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion. | |
| MX2020012130A (es) | Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2. | |
| PH12018500815A1 (en) | Antibody conjugates comprising toll-like receptor agonist | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| PH12018550164A1 (en) | Bcma binding molecules and methods of use thereof | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| MX2022005618A (es) | Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1). | |
| MX2016003103A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores. | |
| MY208638A (en) | Anti-steap1 antigen-binding protein | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| MX2023013995A (es) | Conjugados de anticuerpo y antraciclina. | |
| JOP20220161A1 (ar) | جسم مضاد لـ lilrb1 واستخداماته | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| MX2024006743A (es) | Unidad de union a antigeno ccr8 y usos de los mismos. | |
| MY209796A (en) | Fusion protein constructs for complement associated disease | |
| MX2021000783A (es) | Anticuerpos humanizados contra psma. | |
| MX2021004993A (es) | Materiales y metodos para tratar cancer. | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody |